Mingerlan (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin Hydrochloride and Solifenacin Succinate, the active ingredient in Mingerlan, is an alpha‑1 adrenergic antagonist combined with an antimuscarinic, presented as an oral tablet for oral administration. It targets smooth muscle tone in the prostate and detrusor muscle activity in the bladder, providing symptom relief for benign prostatic hyperplasia and overactive bladder in adult patients.

GNH USA supplies Mingerlan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets through reliable logistics.

Mingerlan combines an alpha‑1 antagonist and an antimuscarinic to treat lower urinary tract disorders. - Benign prostatic hyperplasia (BPH): improves urinary flow and reduces nocturia, hesitancy, and incomplete emptying. - Overactive bladder (OAB): decreases urgency, frequency, and urge incontinence episodes. - Urinary retention secondary to BPH: facilitates bladder emptying and reduces residual volume.

Mingerlan may cause a range of adverse reactions.

Common Side Effects: - Dizziness: transient light‑headedness, especially on standing. - Dry mouth: reduced salivation leading to throat discomfort. - Constipation: slowed gastrointestinal motility. - Headache: mild to moderate pressure sensation. - Orthostatic hypotension: drop in blood pressure upon standing. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Priapism: prolonged painful erection requiring urgent care. - Severe urinary retention: inability to void, may need catheterisation. - Allergic reactions: rash, swelling, or anaphylaxis. - QT interval prolongation: cardiac rhythm disturbance in susceptible patients.

Before prescribing Mingerlan, clinicians should consider several safety measures. - Monitor blood pressure: watch for hypotension, especially after the first dose. - Assess urinary flow: ensure no acute retention before initiating therapy. - Evaluate hepatic function: dose adjustment may be needed in severe impairment. - Caution in narrow‑angle glaucoma: antimuscarinic effect can increase intra‑ocular pressure. - Avoid use in severe hepatic impairment: risk of accumulation. - Store at room temperature: keep in the original pack, protect from moisture.

Mingerlan can interact with other medicines, requiring careful review.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other alpha‑blockers (e.g., doxazosin): additive hypotensive effect. - Concurrent antimuscarinics (e.g., oxybutynin): risk of excessive anticholinergic burden.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: enhanced orthostatic hypotension. - Antihistamines or tricyclic antidepressants: increase anticholinergic side effects.